Comparison of Actinomycin D and Methotrexate in treatment of Mole Hydatiform

Comparison of Actinomycin D and Methotrexate effectiveness in treatment of Gestational Trophoblastic Neoplasia based on bhCG level

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2012062810128N1

Enrollment

Registered

2012-08-31

Start date

2009-10-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gestational Trophoblastic Neoplasia. Mole Hydatiform,Nonspecific Trophoblastic Disease NOS

Interventions

Intervention 1: Control group: weekly pulsed dose of 40 mg/m(2) of methotrexate intramuscularly. Intervention 2: Intervention group:pulsed intravenous bolus of 1.25 mg per square meter of body surface

Treatment - Drugs

Control group: weekly pulsed dose of 40 mg/m(2) of methotrexate intramuscularly

Intervention group:pulsed intravenous bolus of 1.25 mg per square meter of body surface of Actinomycin D every 2 weeks

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Inclusion criteria:All patient in OB/GYN clinic of Emam khomeiny hospital of ahwaz during 2008 to 2010 suffering low risk gestattional trophoblastic neoplasia exclusion criteria: History of chemotherapy(except for non melanotic skin cancer); History of chemotherapy due to GTN; History of malignancy with less than 5 years disease free; Patient with affected function of liver or kidney

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Beta hCG. Timepoint: weekly. Method of measurement: mIu/ml.	—

Secondary

Measure	Time frame
Liver enzyme elevation. Timepoint: weekly. Method of measurement: mIU/ml.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShima Razi

Jundi Shapur Medical Science University

razi-sh@ajums.ac.ir+98 61 1333 7681

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026